Synairgen plc (LON:SNG), a developer of respiratory drugs, has all the building blocks for another successful year. Key going forward will be the company’s collaboration with Pharmaxis developing Lysyl Oxidase type 2 (LOXL2) inhibitor PXS-5382 to treat lung and liver fibrosis, which has entered phase I clinical trials.
Vast Resources PLC (LON:VAST) told investors that it continues to “make good progress” with Mercuria Energy Trading to close the proposed US$9.5mln pre-payment off-take agreement. The company confirmed that it has now issued 565mln share warrants, in accordance with the approvals granted at last month’s shareholder meeting.
Amryt Pharma PLC (LON:AMY) has licensed a non-viral gene therapy platform technology with potential applicability across a range of genetic diseases, including epidermolysis-bullosa (EB). The technology has been licensed from University College Dublin and involves the delivery of gene therapy using high branched poly (β-amino ester) polymer technology.
MySQUAR Limited (LON:MYSQ) has announced the release of its new strategy card mobile game, Wushu King, which focuses on elements of both Chinese and Myanmar folklore.
Redx Pharma Plc (LON:REDX) has announced that its abstract has been accepted for presentation as a poster at the American Association for Cancer Research Annual meeting in Chicago in April.
Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP), the pharmaceutical company focused on oncology and immunotherapy, said Dr Jim Phillips, is to step down as chief executive officer. He will be succeeded by COO, Dr Craig Cook.
Sareum Holdings Plc said a partner developing its lead drug candidate will provide a poster presentation at a top cancer conference taking place next month. Sierra Oncology will outline late-breaking preclinical results for SRA737 at the American Association of Cancer Research in Chicago.
Scotgold Resources Limited (LON:SGZ) has agreed to sell its French business, which owns the French exploration licence. The conditional sale would see Scotgold receive €100,000 as an initial cash payment, along with up to €900,000 of potential deferred cash payments.
African Battery Metals PLC (LON:ABM) posted a higher loss in 2017 as it switched its focus to cobalt in the DRC from gold exploration in Sierra Leone. Roger Murphy, chief executive, said: "In 2018, we expect to significantly advance our exploration activities in battery metals, especially cobalt. Big Pic on Tuesday.
Diversified Gas & Oil plc (LON:DGOC) has landed a US$500mln credit facility which is intended to fund the ambitious oiler as it acquires a large portfolio of assets in the United States. Earlier this month it closed the acquisition of Alliance Petroleum, adding 13,000 wells (addressing some 49mln barrels of reserves) in a deal worth US$95mln and it is approaching a close for a separate US$85mln acquisition which will deliver 11,000 wells (addressing 69mln barrels).
In Berkeley Energia Ltd’s (LON:BKY) financial results the European mine developer highlighted its progress with its flagship Salamanca project, following the completion of a US$120mln with the Oman sovereign wealth fund. The company highlighted that the contracting process has been competitive and as a result it is seeing improved cost for the project.
Metal Tiger PLC (LON:MTR) confirmed that it had made a further purchase of MOD Resources shares, increasing the company’s stake to 5.98%. A stock market statement revealed that Metal Tiger acquired 3.29mln shares on market, with some shares purchased at 4.68 and others bought at 4.655 Australian cents. The company paid a total of A$152,646 for the shares.
APQ Global Limited (LON:APQ), the AIM-listed emerging markets growth company announced that at the close of business on 28 February 2018, its unaudited book value per ordinary share was 127.04 US cents, equivalent to 92.20p.
Capital Network has issued a research report on Midatech Pharma Plc (LON:MTPH) in which analyst Ricardo Lowi concludes that, with the firm’s stock price at multi-year lows, the group’s potential to address a high unmet need in large cancer markets in the near term, suggests an attractive entry point.
Capital Network has issued a research report on Optibiotix Health PLC (LON:OPTI) in which analyst Ricardo Lowi said he expects the group’s rich deal pipeline to translate in to material revenue growth in the upcoming months, against a lean cost base, Lowi concluded that Optibiotix’s valuation points to significant stock price upside over the next 12-18 months.